Literature DB >> 25085588

Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization.

Yue Wei Zhang1, Jin Ao, Ying Liu, Ming Xi Qiao, Xue Ling Yang, Shun Xiong Tang, Chuang Li, Ke Xu.   

Abstract

The objective of this study is to investigate pharmacokinetics of gelatin sponge microparticles (GSMs) combined with epirubicin in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization (TACE). Eighteen successful models of VX2 in New Zealand white rabbits was established, which were divided into three groups randomly: HAI group (n = 6), the epirubicin solution (epirubicin 10 mg mixed with saline 10 ml into the hepatic artery); GSMs-TACE group (n = 6), GSMs (20 mg) mixed with epirubicin solution (1 mg/ml); c-TACE group (n = 6), epirubicin (10 mg) mixed with lipiodol (10 ml). Each rabbit was administrated epirubicin at dose adjusted for a 1 mg/kg. Samples were collected from femoral vein at 5, 10, 20, 30, 40, 60, 90, and 120 min after therapy after 120 min; rabbit was killed, and tumor and peritumoral normal liver tissue was cised. Epirubicin concentrations in plasma and tumor were measured. The epirubicin concentration in plasma was significantly lower in GSMs-TACE group than in HAI group. C max in there groups after administration was 28.77 ± 7.15 μg/ml in c-TACE group, 83.84 ± 32.28 μg/ml in GSMs-TACE group, and 238.46 ± 23.44 μg/ml in HAI group at 5 min, respectively. The epirubicin concentration in tumor tissue was 53.06 ± 16.9 μg/g in c-TACE group, 44.49 ± 16.80 μg/g in the GSMs-TACE group, and 18.32 ± 8.30 μg/g in HAI group, respectively. Epirubicin concentration of GSMs-TACE group was significantly higher than that of HAI group (P < 0.05). The area under the curve (AUC) at 0-120 min in c-TACE, GSMs-TACE, and HAI groups were 1,815 ± 889.88, 3,416 ± 799.90, and 11,899 ± 2,717.17 μg min/ml, respectively. The AUC was lower in GSMs-TACE group than in HAI group (P < 0.05). Compared with HAI, GSMs-TACE has higher epirubicin concentrations in tumor and lower concentrations in plasma. The results show that GSMs-TACE has a feature of slow drug release-it may be one of the mechanisms of GSMs-TACE for HCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25085588     DOI: 10.1007/s13277-014-2408-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  19 in total

1.  [Transcatheter arterial chemoembolization of hepatocellular carcinoma with 350-560μm gelatin sponge particles: efficacy, tumour response and survival].

Authors:  Yue-wei Zhang; Ying Liu
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2013-08

2.  In vivo anti-tumor effect of dual release of cisplatin and adriamycin from biodegradable gelatin hydrogel.

Authors:  Mitsunaga Konishi; Yasuhiko Tabata; Masatoshi Kariya; Hossein Hosseinkhani; Ayako Suzuki; Ken Fukuhara; Masaki Mandai; Kenji Takakura; Shingo Fujii
Journal:  J Control Release       Date:  2004-12-15       Impact factor: 9.776

3.  A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma.

Authors:  Hannah van Malenstein; Geert Maleux; Vincent Vandecaveye; Sam Heye; Wim Laleman; Jos van Pelt; Johan Vaninbroukx; Frederik Nevens; Chris Verslype
Journal:  Onkologie       Date:  2011-06-21

4.  [The preliminary study of recombinant adenovirus p53 combined with transarterial embolization with particles for advanced hepatocellular carcinoma].

Authors:  Jun Zhou; Yuewei Zhang; Guangsheng Zhao; Ying Liu; Chuang Li; Shunxiong Tang; Song Liu; Lin Yuan
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2014-03-11

5.  Synthesis of gelatin microspheres containing interferon.

Authors:  Y Tabata; Y Ikada
Journal:  Pharm Res       Date:  1989-05       Impact factor: 4.200

6.  Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor model.

Authors:  J N Munck; M Riggi; P Rougier; G G Chabot; L H Ramirez; Z Zhao; C Bognel; P Ardouin; P Herait; A Gouyette
Journal:  Cancer Res       Date:  1993-04-01       Impact factor: 12.701

7.  Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report.

Authors:  T Konno; H Maeda; K Iwai; S Tashiro; S Maki; T Morinaga; M Mochinaga; T Hiraoka; I Yokoyama
Journal:  Eur J Cancer Clin Oncol       Date:  1983-08

Review 8.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Andrew Burroughs; Jordi Bruix
Journal:  Lancet       Date:  2003-12-06       Impact factor: 79.321

9.  Tumor models and specific contrast agents for small animal imaging in oncology.

Authors:  Yicheng Ni; Huaijun Wang; Feng Chen; Junjie Li; Frederik DeKeyzer; Yuanbo Feng; Jie Yu; Hilde Bosmans; Guy Marchal
Journal:  Methods       Date:  2009-03-26       Impact factor: 3.608

10.  In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors.

Authors:  J B Kruskal; L Hlatky; P Hahnfeldt; K Teramoto; K R Stokes; M E Clouse
Journal:  J Vasc Interv Radiol       Date:  1993 Nov-Dec       Impact factor: 3.464

View more
  8 in total

Review 1.  Advances in Biomaterials and Technologies for Vascular Embolization.

Authors:  Jingjie Hu; Hassan Albadawi; Brian W Chong; Amy R Deipolyi; Rahul A Sheth; Ali Khademhosseini; Rahmi Oklu
Journal:  Adv Mater       Date:  2019-06-06       Impact factor: 30.849

2.  Delayed and Aberrant Presentation of VX2 Carcinoma in a Rabbit Model of Hepatic Neoplasia.

Authors:  Sarah A Hansen; Michael K Fink; Anandhi Upendran; Cynthia L Besch-Williford; Robert S Livingston; James M Amos-Landgraf; Jimmy C Lattimer; Raghuraman Kannan
Journal:  Comp Med       Date:  2015-10       Impact factor: 0.982

3.  Gelatin sponge microparticles for the treatment of the spontaneous rupture of hepatocellular carcinoma hemorrhage.

Authors:  Pu Zhao Wu; Jun Zhou; Yue Wei Zhang
Journal:  Exp Ther Med       Date:  2016-08-04       Impact factor: 2.447

4.  Percutaneous ultrasound guided implantation of VX2 for creation of a rabbit hepatic tumor model.

Authors:  Sarah B White; Jeane Chen; Andrew C Gordon; Kathleen R Harris; Jodi R Nicolai; Derek L West; Andrew C Larson
Journal:  PLoS One       Date:  2015-04-08       Impact factor: 3.240

5.  Modeling pre-metastatic lymphvascular niche in the mouse ear sponge assay.

Authors:  Melissa García-Caballero; Maureen Van de Velde; Silvia Blacher; Vincent Lambert; Cédric Balsat; Charlotte Erpicum; Tania Durré; Frédéric Kridelka; Agnès Noel
Journal:  Sci Rep       Date:  2017-01-27       Impact factor: 4.379

6.  350-560 μm gelatin sponge particles combined with transcatheter arterial chemoembolization for the treatment of elderly hepatocellular carcinoma: The safety and efficacy.

Authors:  Guang Sheng Zhao; Chuang Li; Ying Liu; Zhi Zhong Ren; Xiao Lin Yuan; Jun Zhou; Yue Wei Zhang; Ming Zhang
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

7.  Clinical application of gelatin sponge microparticles-transcatheter arterial chemoembolization combined with synchronous antigen-presenting dendritic cell sequential reinfusion for treatment of advanced large liver cancer: A single-center, prospective, non-randomized, controlled trial.

Authors:  Guang Sheng Zhao; Song Liu; Ying Liu; Chuang Li; Ruo Yu Wang; Jie Bian; Rui Ping Zhu; Jun Zhou; Yue Wei Zhang
Journal:  Medicine (Baltimore)       Date:  2022-02-25       Impact factor: 1.817

8.  MRI visible drug eluting magnetic microspheres for transcatheter intra-arterial delivery to liver tumors.

Authors:  Dong-Hyun Kim; Jeane Chen; Reed A Omary; Andrew C Larson
Journal:  Theranostics       Date:  2015-02-07       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.